{"url_path":"/sec/spro/8-k/2026-06-25/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-283033-index.html","accession_number":"0001193125-26-283033","cik":"0001701108","ticker":"SPRO","issuer_name":"Spero Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-283033-index.html","primary_entity_key":"0001701108","primary_entity_name":"Spero Therapeutics, Inc."},"word_count":124,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits\n\n \n\n(d)\n\nExhibits\n\n \n\nExhibit No.\n\n  \n\nDescription\n\n3.1\n  \n[Certificate of Amendment to Restated Certificate of Incorporation of Spero Therapeutics, Inc.](d86736dex31.htm)\n\n99.1\n  \n[Spero Therapeutics, Inc. 2026 Stock Incentive Plan (incorporated by reference to Exhibit 99.1 of registrant’s Registration Statement on Form S-8 (File No. 333-296972) filed with the SEC on June 23, 2026)](http://www.sec.gov/Archives/edgar/data/1701108/000119312526279429/d155753dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)\n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: June 25, 2026\n \n\n \nSPERO THERAPEUTICS, INC.\n\n \n\n \nBy:\n \n\n/s/ Esther Rajavelu\n\n \n\n \n\n \nEsther Rajavelu\n\n \n\n \n\n \nChief Executive Officer and Chief Financial Officer"}